(Q38160887)

30 August 2017

0 references

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis (English)

1 reference

30 August 2017

1 reference

1 reference

1 reference

O J Phung

1

1 reference

30 August 2017

D M Sobieraj

series ordinal

2

1 reference

30 August 2017

S S Engel

series ordinal

3

1 reference

30 August 2017

S N Rajpathak

series ordinal

4

1 reference

30 August 2017

publication date

16 December 2013

1 reference

Diabetes, Obesity and Metabolism

30 August 2017

published in

1 reference

30 August 2017

volume

16

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

410-417

1 reference

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

30 August 2017

cites work

1 reference

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.

21 January 2018

1 reference

Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?

21 January 2018

1 reference

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

Meta-analysis in clinical trials

21 January 2018

1 reference

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

21 January 2018

1 reference

Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes

21 January 2018

1 reference

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

21 January 2018

1 reference

Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.

21 January 2018

1 reference

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.

21 January 2018

1 reference

Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients

21 January 2018

1 reference

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve ty

21 January 2018

1 reference

Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

21 January 2018

1 reference

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

21 January 2018

1 reference

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

21 January 2018

1 reference

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus

21 January 2018

1 reference

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12233

1 reference

30 August 2017

1 reference